Title: CAR T cells; looking toward the future of CAR T treatment

FDA has approved CAR T treatment for leukemia ,lymphoma and multiple myeloma patients.
Yet, solid tumors raise major challenge for CAR T cell treatment which includes; antigen specificity, infiltration into the solid tumor, coping with tumor microenvironment and manufacturing concerns. One of our solutions to overcome toxicity of CAR T cells while having better infiltration are EVs derived CAR T cells, which contains similar profile as their parental cells with similar cytotoxicity abilities. Using CAR T EVs rather than CAR-T cells provides an immunotherapeutic approach that may reach solid tumors inner mass, and improve therapeutic efficacy while reducing costs and risks. However manufacturing CAR Ts are another obstacle. Thus producing an in vivo off-the-shelf treatment bypasses the labor demanding of ex vivo engineering. We established a lentiviral drug to redirect and reprogram endogenous T cells toward tumors. By this, CAR T cells may be a simple solution for multiple patients around the world.